论文部分内容阅读
携带药物的纳米颗粒可以有选择地瞄准肿瘤细胞,但其有效性尚需临床试验来证明。人体试验的结果令人震惊。一位病人仅仅静脉注射了两小时的一种实验性抗癌药物,剂量较平时还要小,体内的双肺多发转移瘤就开始缩小,有的甚至消失不见。另一位病人接受了6个月治疗后,体内的宫颈瘤缩小了近60%。此次由位于美国马萨诸塞州剑桥市的生物科学公司Bind Biosciences设计的药物试验,只是为了证明这项基于纳米技术的实验性疗法是否安全。但是,令人倍受鼓舞的试验结果再一次点燃了人们对于纳米药物的希望。十多年来,
Drug-bearing nanoparticles can selectively target tumor cells, but its effectiveness is still in clinical trials to prove. The results of human trials are alarming. A patient is only an intravenous injection of two hours of an experimental anti-cancer drugs, the dose is smaller than usual, the body’s lung multiple metastases began to shrink, and some even disappear. Another patient received 6 months of treatment, the body of cervical tumor narrowed nearly 60%. The drug test, designed by Bind Biosciences, a bioscience company based in Cambridge, Massachusetts, just to prove that this nanotechnology-based experimental therapy is safe. However, the encouraging test results once again ignited the hope for nanomedicine. More than a decade,